TRCT
ACRV icon

Tower Research Capital (TRC)’s Acrivon Therapeutics ACRV Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98K Sell
1,677
-2,849
-63% -$4.84K ﹤0.01% 4592
2026
Q1 		$6.29K Buy
+4,526
New +$7.89K ﹤0.01% 4064
2025
Q4 		– Sell
-8,736
Closed -$15.8K – 5114
2025
Q3 		$15.8K Sell
8,736
-108
-1% -$152 ﹤0.01% 3518
2025
Q2 		$10.5K Buy
8,844
+5,754
+186% +$7.9K ﹤0.01% 3944
2025
Q1 		$6.27K Buy
3,090
+1,324
+75% +$7.13K ﹤0.01% 4055
2024
Q4 		$10.6K Sell
1,766
-2,989
-63% -$21.7K ﹤0.01% 3789
2024
Q3 		$33.3K Buy
4,755
+976
+26% +$7.69K ﹤0.01% 2947
2024
Q2 		$21.9K Buy
3,779
+2,962
+363% +$23.9K ﹤0.01% 3705
2024
Q1 		$5.84K Sell
817
-1,201
-60% -$5.58K ﹤0.01% 4481
2023
Q4 		$9.93K Buy
2,018
+763
+61% +$4.03K ﹤0.01% 4326
2023
Q3 		$12K Buy
1,255
+523
+71% +$6.04K ﹤0.01% 3936
2023
Q2 		$9.49K Sell
732
-360
-33% -$4.36K ﹤0.01% 4274
2023
Q1 		$14K Buy
1,092
+933
+587% +$15.7K ﹤0.01% 3856
2022
Q4 		$2K Buy
+159
New +$2.02K ﹤0.01% 5315

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s ACRV Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Acrivon Therapeutics (ACRV) stake by 63% in Q2 2026, selling an estimated $4.84K and leaving 1,677 shares worth $2.98K. The position accounts for ﹤0.01% of the portfolio, ranked #4592.

Tower Research Capital (TRC) first reported a position in ACRV in Q4 2022 and has held it in 14 quarters since. The position peaked at $33.3K in Q3 2024. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Tower Research Capital (TRC) held 1,677 shares of Acrivon Therapeutics worth $2.98K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,849 Acrivon Therapeutics shares in Q2 2026, an estimated $4.84K.
  • Acrivon Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4592 holding.
  • Tower Research Capital (TRC) first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Acrivon Therapeutics position peaked at $33.3K in Q3 2024.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.